Cargando…
Generation of Chimeric “ABS Nanohemostat” Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model
Purpose. Using the classical Ankaferd Blood Stopper (ABS) solution to create active hemostasis during partial nephrectomy (PN) may not be so effective due to insufficient contact surface between the ABS hemostatic liquid agent and the bleeding area. In order to broaden the contact surface, we genera...
Autores principales: | Huri, Emre, Beyazit, Yavuz, Mammadov, Rashad, Toksoz, Sila, Tekinay, Ayse B., Guler, Mustafa O., Ustun, Huseyin, Kekilli, Murat, Dadali, Mumtaz, Celik, Tugrul, Astarci, Müzeyyen, Haznedaroglu, Ibrahim C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590747/ https://www.ncbi.nlm.nih.gov/pubmed/23509463 http://dx.doi.org/10.1155/2013/949460 |
Ejemplares similares
-
Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level
por: Huri, Emre, et al.
Publicado: (2016) -
Antineoplastic Effects of Ankaferd Hemostat
por: Malkan, Umit Yavuz, et al.
Publicado: (2022) -
Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System
por: Akbal, Erdem, et al.
Publicado: (2013) -
Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
por: Ciftciler, Rafiye, et al.
Publicado: (2020) -
Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content
por: Beyazit, Fatma, et al.
Publicado: (2020)